5 Essential Elements For "3
All enrolled sufferers who been given no less than 1 dose of zosuquidar or placebo during induction ended up monitored with the occurrence of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The most common adverse functions were being associated with the period of prolonged and important myelosuppression as is expected with in